{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T17:33:17Z","timestamp":1776274397735,"version":"3.50.1"},"reference-count":35,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,2,6]],"date-time":"2022-02-06T00:00:00Z","timestamp":1644105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The SARS-CoV-2 pandemic caused a massive health and societal crisis, although the fast development of effective vaccines reduced some of the impact. To prepare for future respiratory virus pandemics, a pan-viral prophylaxis could be used to control the initial virus outbreak in the period prior to vaccine approval. The liposomal vaccine adjuvant CAF\u00ae09b contains the TLR3 agonist polyinosinic:polycytidylic acid, which induces a type I interferon (IFN-I) response and an antiviral state in the affected tissues. When testing CAF09b liposomes as a potential pan-viral prophylaxis, we observed that intranasal administration of CAF09b liposomes to mice resulted in an influx of innate immune cells into the nose and lungs and upregulation of IFN-I-related gene expression. When CAF09b liposomes were administered prior to challenge with mouse-adapted influenza A\/Puerto Rico\/8\/1934 virus, it protected from severe disease, although the virus was still detectable in the lungs. However, when CAF09b liposomes were administered after influenza challenge, the mice had a similar disease course to controls. In conclusion, CAF09b may be a suitable candidate as a pan-viral prophylactic treatment for epidemic viruses, but must be administered prior to virus exposure to be effective.<\/jats:p>","DOI":"10.3390\/ijms23031850","type":"journal-article","created":{"date-parts":[[2022,2,6]],"date-time":"2022-02-06T20:36:47Z","timestamp":1644179807000},"page":"1850","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["A Novel Prophylaxis Strategy Using Liposomal Vaccine Adjuvant CAF09b Protects against Influenza Virus Disease"],"prefix":"10.3390","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6442-6439","authenticated-orcid":false,"given":"Julie","family":"Zimmermann","sequence":"first","affiliation":[{"name":"Center for Vaccine Research, Statens Serum Institut, 2300 Copenhagen S, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Signe","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Center for Vaccine Research, Statens Serum Institut, 2300 Copenhagen S, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramona","family":"Trebbien","sequence":"additional","affiliation":[{"name":"Department of Virus and Microbiological Special Diagnostics, Statens Serum Institut, 2300 Copenhagen S, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Cox","sequence":"additional","affiliation":[{"name":"Influenza Centre, Department of Clinical Science, University of Bergen, 5020 Bergen, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9918-3422","authenticated-orcid":false,"given":"Fan","family":"Zhou","sequence":"additional","affiliation":[{"name":"Influenza Centre, Department of Clinical Science, University of Bergen, 5020 Bergen, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Follmann","sequence":"additional","affiliation":[{"name":"Center for Vaccine Research, Statens Serum Institut, 2300 Copenhagen S, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Pedersen","sequence":"additional","affiliation":[{"name":"Center for Vaccine Research, Statens Serum Institut, 2300 Copenhagen S, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis","family":"Christensen","sequence":"additional","affiliation":[{"name":"Center for Vaccine Research, Statens Serum Institut, 2300 Copenhagen S, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Buschmann, M.D., Carrasco, M.J., Alishetty, S., Paige, M., Alameh, M.G., and Weissman, D. (2021). Nanomaterial Delivery Systems for mRNA Vaccines. Vaccines, 9.","DOI":"10.3390\/vaccines9010065"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41579-021-00573-0","article-title":"SARS-CoV-2 variants, spike mutations and immune escape","volume":"19","author":"Harvey","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/14760584.2021.1903879","article-title":"Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies","volume":"20","author":"Bian","year":"2021","journal-title":"Expert Rev. Vaccines"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.4049\/jimmunol.1402033","article-title":"TLR3-mediated CD8+ dendritic cell activation is coupled with establishment of a cell-intrinsic antiviral state","volume":"195","author":"Meissner","year":"2015","journal-title":"J. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.chom.2020.05.008","article-title":"Type I and Type III Interferons\u2014Induction, Signaling, Evasion, and Application to Combat COVID-19","volume":"27","author":"Park","year":"2020","journal-title":"Cell Host Microbe"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"104811","DOI":"10.1016\/j.antiviral.2020.104811","article-title":"Antiviral activities of type I interferons to SARS-CoV-2 infection","volume":"179","author":"Mantlo","year":"2020","journal-title":"Antivir. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1126\/science.abc6027","article-title":"Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients","volume":"369","author":"Hadjadj","year":"2020","journal-title":"Science"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.coviro.2011.11.001","article-title":"Induction and function of type I and III interferon in response to viral infection","volume":"1","author":"Levy","year":"2011","journal-title":"Curr. Opin. Virol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.mib.2010.05.009","article-title":"Viral tricks to grid-lock the type I interferon system","volume":"13","author":"Versteeg","year":"2010","journal-title":"Curr. Opin. Microbiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.antiviral.2018.03.005","article-title":"PrEP-001 prophylactic effect against rhinovirus and influenza virus\u2014RESULTS of 2 randomized trials","volume":"153","author":"Malcolm","year":"2018","journal-title":"Antivir. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"14085","DOI":"10.1038\/s41598-019-50365-z","article-title":"HCV p7 as a novel vaccine-target inducing multifunctional CD4(+) and CD8(+) T-cells targeting liver cells expressing the viral antigen","volume":"9","author":"Filskov","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Filskov, J., Mikkelsen, M., Hansen, P.R., Christensen, J.P., Thomsen, A.R., Andersen, P., Bukh, J., and Agger, E.M. (2017). Broadening CD4(+) and CD8(+) T Cell Responses against Hepatitis C Virus by Vaccination with NS3 Overlapping Peptide Panels in Cross-Priming Liposomes. J. Virol., 91.","DOI":"10.1128\/JVI.00130-17"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3927","DOI":"10.1016\/j.vaccine.2014.05.050","article-title":"Induction of CD8+ T-cell responses against subunit antigens by the novel cationic liposomal CAF09 adjuvant","volume":"32","author":"Korsholm","year":"2014","journal-title":"Vaccine"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.smim.2018.10.003","article-title":"Immunocorrelates of CAF family adjuvants","volume":"39","author":"Pedersen","year":"2018","journal-title":"Semin. Immunol."},{"key":"ref_15","first-page":"640","article-title":"Phase I trials of poly(I,C) complexes in advanced cancer","volume":"4","author":"Krown","year":"1985","journal-title":"J. Biol. Response Mod."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejpb.2010.10.001","article-title":"Incorporation of a synthetic mycobacterial monomycoloyl glycerol analogue stabilizes dimethyldioctadecylammonium liposomes and potentiates their adjuvant effect in vivo","volume":"77","author":"Nordly","year":"2011","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1365-2567.2007.02560.x","article-title":"The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomes","volume":"121","author":"Korsholm","year":"2007","journal-title":"Immunology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jconrel.2016.08.034","article-title":"The administration route is decisive for the ability of the vaccine adjuvant CAF09 to induce antigen-specific CD8+ T-cell responses: The immunological consequences of the biodistribution profile","volume":"239","author":"Schmidt","year":"2016","journal-title":"J. Control Release"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/35099560","article-title":"Recognition of double-stranded RNA and activation of NF-\u03baB by Toll-like receptor 3","volume":"413","author":"Alexopoulou","year":"2001","journal-title":"Nature"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/ni1087","article-title":"The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses","volume":"5","author":"Yoneyama","year":"2004","journal-title":"Nat. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/cr.2015.9","article-title":"Cationic nanocarriers induce cell necrosis through impairment of Na+\/K+-ATPase and cause subsequent inflammatory response","volume":"25","author":"Wei","year":"2015","journal-title":"Cell Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1189\/jlb.4VMR1114-555R","article-title":"Neutrophils in viral infections: Current concepts and caveats","volume":"98","author":"Galani","year":"2015","journal-title":"J. Leukoc. Biol."},{"key":"ref_23","first-page":"112","article-title":"Natural killer cells in antiviral immunity","volume":"22","author":"Strunz","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S2213-2600(20)30511-7","article-title":"Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: A randomised, double-blind, placebo-controlled, phase 2 trial","volume":"9","author":"Monk","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.3389\/fimmu.2020.01061","article-title":"Interferon-\u03b12b Treatment for COVID-19","volume":"11","author":"Zhou","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.chom.2016.01.007","article-title":"Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice","volume":"19","author":"Channappanavar","year":"2016","journal-title":"Cell Host Microbe"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"11416","DOI":"10.1128\/JVI.78.20.11416-11421.2004","article-title":"Resolution of primary severe acute respiratory syndrome-associated coronavirus infection requires Stat1","volume":"78","author":"Hogan","year":"2004","journal-title":"J. Virol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.vaccine.2005.08.102","article-title":"Obstacles and advances in SARS vaccine development","volume":"24","author":"Taylor","year":"2006","journal-title":"Vaccine"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S0091-6749(03)02025-6","article-title":"Innate immune activation as a broad-spectrum biodefense strategy: Prospects and research challenges","volume":"112","author":"Hackett","year":"2003","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1172\/JCI0215536","article-title":"Noncoding RNA danger motifs bridge innate and adaptive immunity and are potent adjuvants for vaccination","volume":"110","author":"Wang","year":"2002","journal-title":"J. Clin. Investig."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2016.12.007","article-title":"Prophylactic and therapeutic intranasal administration with an immunomodulator, Hiltonol\u00ae (Poly IC:LC), in a lethal SARS-CoV-infected BALB\/c mouse model","volume":"139","author":"Kumaki","year":"2017","journal-title":"Antivir. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000503030","article-title":"Innate Immune Evasion by Human Respiratory RNA Viruses","volume":"12","author":"Kikkert","year":"2020","journal-title":"J. Innate Immun."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41385-020-00355-6","article-title":"Genetic influences on viral-induced cytokine responses in the lung","volume":"14","author":"Forbester","year":"2021","journal-title":"Mucosal Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/cid\/ciab376","article-title":"Differential Cytokine Signatures of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Influenza Infection Highlight Key Differences in Pathobiology","volume":"74","author":"Karaba","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2\u2212\u0394\u0394CT Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/3\/1850\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:15:03Z","timestamp":1760134503000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/3\/1850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,6]]},"references-count":35,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["ijms23031850"],"URL":"https:\/\/doi.org\/10.3390\/ijms23031850","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,6]]}}}